Hydroxyurea Exposure in Lactation: a Pharmacokinetics Study (HELPS).
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 32171562.
- Also identified by DOI 10.1016/j.jpeds.2020.02.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Lactation is contraindicated for women with sickle cell anemia receiving hydroxyurea therapy, despite sparse pharmacokinetics data. In 16 women who were lactating volunteers, we documented hydroxyurea transferred into breastmilk with a relative infant dosage of 3.4%, which is below the recommended 5%-10% safety threshold. Breastfeeding should be permitted for women taking daily oral hydroxyurea.
Medical subject headings
- Anemia, Sickle Cell
- Hydroxyurea
- Lactation
- Milk, Human